About Us
Passionate About
Patient Solutions
We are a patient-centric, commercial-stage biopharmaceutical company whose product is FDA approved for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. We are also dedicated to the continued clinical investigation of etripamil as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR).
Since our founding, our unwavering focus has been on developing treatment solutions that can be self-administered when needed based on clinically-validated mechanisms of action.
Our approach minimizes overhead and focuses spending on what matters most: developing treatment solutions that fill an unmet need and alleviating the burdens for people living with episodic cardiovascular conditions and their families.
Over the past decade, Milestone has assembled a team of leading pharmaceutical executives with decades of experience in drug research and development. Our leadership team brings extensive expertise in cardiovascular medicine, clinical drug development, regulatory affairs, quality assurance, manufacturing, and commercialization.
Patient Advocacy
At Milestone, everything we do is with the patient in mind. To that end, we partner with groups and organizations who share our dedication to support and educate people with episodic cardiovascular conditions.
Our Mission
Milestone is committed to improving the lives of people
living with episodic cardiovascular conditions.
Our Mission
Milestone is committed to improving the lives of people living with episodic cardiovascular conditions.
.png){kind=small}